visfatin/pbef/nampt: a new cardiovascular target?

Clicks: 267
ID: 212270
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In the last years, a growing interest has emerged towards understanding the role of adipocytokines in the development of cardiometabolic complications. Five years ago, visfatin/PBEF/Nampt was identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/PBEF/Nampt was initially claimed as a potentially beneficial molecule due to its insulin-mimetic and glucose-lowering properties. Nevertheless, growing evidence has since then unveiled that visfatin/PBEF/Nampt may rather be a biomarker of inflammation and endothelial damage, and also a direct regulator of the cardiovascular system that modulates cell proliferation and survival, extracellular matrix, vascular reactivity and inflammation. On one side, the blockade of the deleterious cardiovascular actions of visfatin/PBEF/Nampt is being regarded as a potential approach to prevent and treat, not only cardio-metabolic complications, but also other pathologies implying excessive angiogenesis. Conversely, the administration of visfatin/PBEF/Nampt has shown beneficial effects in different ischemic conditions. Further research is required to evaluate the real value of visfatin/PBEF/Nampt as a pharmacological target.
Reference Key
epeir2010frontiersvisfatin/pbef/nampt: Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Concepción ePeiró;Tania eRomacho;Raffaele eCarraro;Raffaele eCarraro;Carlos F Sánchez-Ferrer
Journal chemical research in chinese universities
Year 2010
DOI
10.3389/fphar.2010.00135
URL
http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00135/full
Keywords
inflammation cardioprotection cardiovascular proliferation atherosclerosis pharmacology adipocytokinetherapeutics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.